## JNNN

**Discussions with leaders:** David Mankoff, associate editor for *JNM*, talked with Chi Van Dang and Elizabeth Jaffee about their leadership in guiding national priorities for translational cancer research and perspectives on the roles of molecular imaging and theranostics. **Page 637** 

<sup>11</sup>C-Methionine PET in pediatric glioma: Bag and colleagues assess whether <sup>11</sup>C-methionine PET detection of functionally active tumors is useful for further evaluating MRI changes related to tumor recurrence during routine surveillance of pediatric high-grade gliomas.......... Page 664

<sup>90</sup>Y radioembolization in NETs: Schaarschmidt and colleagues analyze the use of <sup>90</sup>Y radioembolization in neuroendocrine tumor patients with hepatic metastases and look at potential applications in a multimodal treatment approach.

..... Page 679

<sup>89</sup>Zr-Durvalumab PET in NSCLC: Smit and colleagues detail the safety and efficacy of PET/ CT with this <sup>89</sup>Zr-labeled anti–programmed death ligand 1 monoclonal antibody in advanced-stage non–small cell lung cancer and explore correlations **Utility of ER imaging:** Okazawa offers perspective on the usefulness and challenges of <sup>18</sup>F-FES imaging assessment of estrogen receptor expression and previews an article in this issue of *JNM* on the promise of <sup>18</sup>F-4FMFES, a new homolog. *Page 700* 

<sup>90</sup>Y-FAPI therapy for advanced cancer: Ferdinandus and colleagues discuss initial experience with the feasibility and safety of this fibroblastactivation protein-targeted radioligand therapy in extensively pretreated patients with solid tumors. Page 727

<sup>18</sup>F-DCFPyL, <sup>18</sup>F-FDG, and <sup>18</sup>F-NaF in metastatic PCa: Fourquet and colleagues compare the performance of these <sup>18</sup>F-labeled PET/CT agents in lesion detection, agreement, and associations with diagnostic factors in a prospective cohort of men with metastatic prostate cancer. .... Page 735

Specific activity and <sup>18</sup>F-rhPSMA-7.3 uptake: Langbein and colleagues investigate whether the time between synthesis and injection of this **Brain stem hypermetabolism in ALS/FTD:** Zanovello and colleagues use <sup>18</sup>F-FDG PET/MR imaging to investigate spatial patterns of metabolic changes in the brain stem and cervical spinal cord in patients within the amyotrophic lateral sclerosis/frontotemporal dementia continuum.

..... Page 777

**GLP-1 receptor imaging:** Lee and States provide commentary on an article in this issue of *JNM* demonstrating a stepwise approach to glucagonlike peptide-1 receptor-targeting radiotracer development from the laboratory to the clinic......*Page 792* 

**GLP1R imaging in type 2 diabetes:** Eriksson and colleagues present an optimized and simplified <sup>68</sup>Ga-exendin4 PET/CT protocol to enable reproducible imaging of glucagonlike peptide-1 receptor in the pancreas, with potential for long-term diabetes monitoring and future therapies. ...... Page 794